BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProSensa B.V. Initiates Clinical Development of PRO044 in an Open Label Phase I/II Study


3/30/2010 4:13:38 PM

Leiden, March 30th, 2010 / b3c newswire / – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics announces the start of a phase I/II clinical study for PRO044 in patients with Duchenne Muscular Dystrophy.

The objective of this open label, dose-escalating study is to evaluate the safety and tolerability of the systemic delivery of PRO044 in twelve Duchenne Muscular Dystrophy (DMD) patients receiving weekly subcutaneous injections for a period of five weeks. The effect of PRO044 will be assessed at the RNA level, to demonstrate specific exon 44 skipping, and at the protein level, to demonstrate novel dystrophin expression in muscle biopsies.

The first patients have been enrolled at the University Hospital Leuven in Belgium by principal investigator Dr. Nathalie Goemans, department of Pediatric Neurology. Prosensa also received approval from the regulatory authorities in Sweden, where patient screening has been initiated, and Italy. Participating centers are the Queen Silvia Children’s Hospital in Gothenburg, Sweden and the University of Ferrara in Italy.

PRO044 is Prosensa’s second RNA based therapeutic candidate for the treatment of DMD. Prosensa’s lead DMD compound, PRO051/GSK2402968, is close to entering phase III clinical development and was recently partnered with GlaxoSmithKline (GSK). GSK also has an exclusive option on PRO044, which will be triggered upon successful completion of this phase I/II study.

“We are delighted to advance a second promising candidate for the treatment of DMD into clinical development. With the addition of PRO044 to our drug candidate portfolio, we will be able to address a broader patient population upon successful completion of these clinical development programs.” commented Dr. Giles Campion, Chief Medical Officer of Prosensa. “This important clinical development step confirms Prosensa’s commitment to the treatment of neuromuscular disorders.”


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES